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Protein synthesis is critically dependent on transfer (t)-RNAs, but the factors regulating tRNA function are
poorly understood. In this issue ofCell Metabolism, Wei et al. (2015) show that Cdk5 regulatory subunit-asso-
ciated protein-like-1 synchronizes mitochondrial and cytosolic translation in response to external stress,
providing key insight into the pathogenesis of a common inherited mitochondrial disease.Functional tRNA molecules provide the
direct link between the DNA and protein,
enabling the coordinated recruitment of
amino acids based on the DNA transcript
that determines the peptide secondary
sequence. All tRNA molecules require
a wide variety of posttranscriptionally
modified nucleosides which stabilize
tRNA structure, enable efficient interac-
tion with the ribosome, and fine-tune
the translation machinery (Machnicka
et al., 2015). Several distinct enzymes
have been shown to posttranscriptionally
modify cytosolic tRNAs at over 100
different positions (Machnicka et al.,
2013), and in the mitochondrion, 15 spe-
cies of modified nucleosides have been
described modifying 118 tRNA sites
(Suzuki and Suzuki, 2014). The location
and type of modification vary greatly
between different tRNA molecules, or-
ganisms, and tissues. Physiological envi-
ronment and growth conditions influence
the RNA modification pattern, raising the
possibility that tRNA modification may
be important in synchronizing translation
to the needs of the organism at that
particular time (Machnicka et al., 2013).
However, the exact role of these modifi-
cations is largely unknown. It is also
intriguing that cytoplasmic and mito-
chondrial translation share several key
components. For example, a regulatory
role of aminoacyl-tRNA synthetases has
been proposed for both cytosolic and
mitochondrial translation, and two amino-
acyl tRNA synthetases (GARS, KARS)
are present in both the cytoplasm and
mitochondria.
In this issue of Cell Metabolism, Wei
et al. (2015) suggest that tRNA modifi-
cation synchronizes protein translation
within cytosolic and mitochondrial com-partments, provide additional experi-
mental evidence that mitochondrial (mt)-
tRNAs modification has a role in stress
adaptation, and finally show how this
may contribute to the pathomechanism
of mitochondrial diseases.
The disruption of intramitochondrial
protein synthesis leads to biochemical
defects affecting multiple subunits of the
mitochondrial respiratory chain, causing
severe human diseases. Many of these
patients have a primary pathogenic
mutation of mitochondrial DNA (mtDNA)
which directly affects the mitochondrial
(mt)-tRNA or mt-RNA genes, but approx-
imately one-third of patients have a pre-
sumed nuclear genetic disorder. Defining
themolecular basis of this group has been
particularly challenging, but recent ad-
vances in massively parallel sequencing
have revealed several new disease genes,
and unraveled the mechanisms of both
intramitochondrial and cytoplasmic trans-
lation machinery—and particularly the
role of tRNA modification (Figure 1).
Myopathy, lactic acidosis and sidero-
blastic anemia (MLASA) has been asso-
ciated with mutations in pseudouridylate
synthase 1 (PUS1), an enzyme located
in both nucleus and mitochondria.
PUS1 converts uridine into pseudouri-
dine in several cytosolic and mitochon-
drial tRNA positions, thereby increasing
the efficiency of protein synthesis in
both compartments (Fernandez-Vizarra
et al., 2007). Mutations in the methionyl-
tRNA formyltransferase (MTFMT) gene,
responsible for the N-formylation of the
initiator tRNAMet in mitochondria, result
in Leigh syndrome. Unlike all other trans-
lation systems, mitochondria use a single
tRNAMet for both initiation and elonga-
tion. A portion of Met-tRNAMet is formy-Cell Metabolismlated for initiation, whereas the remainder
is used for elongation (Boczonadi and
Horvath, 2014). Autosomal recessive
mutations in the tRNA 5-methylamino-
methyl-2-thiouridylate methyltransferase
(TRMU) enzyme have been reported in
reversible infantile liver disease. TRMU
is responsible for the thiouridylation of
the uridine at the first anticodon position
(U34, wobble position), only present
in the anticodon of three mt-tRNAs
(Glu, Lys, and Gln). The 2-thio group is
required for the efficient codon recogni-
tion, and interestingly, a modifying role
of dietary cysteine intake has been
suggested in the manifestation of the dis-
ease (Boczonadi and Horvath, 2014).
Deficiency of the mitochondrial transla-
tion optimization factor 1 (MTO1) enzyme
that catalyzes the 5-carboxymethyla-
mino-methylation of the same U34
at the wobble position in mt-tRNAGlu,
mt-tRNAGln and mt-tRNALys was re-
ported in patients with infantile hypertro-
phic cardiomyopathy (Boczonadi and
Horvath, 2014). Furthermore, a tissue-
specific regulatory role of MTO1 has
been recently suggested in fine-tuning
mitochondrial translation and balancing
mitochondrial and cellular secondary
stress responses (Tischner et al., 2014).
Mutations in TRIT1 encoding a human
tRNA isopentenyltransferase, which is
responsible for i6A37 modification of
the anticodon loops of a small subset
of cytosolic and mitochondrial tRNAs,
were identified in a patient with severe
epileptic encephalopathy, diabetes melli-
tus. Here the abnormal mitochondrial
protein synthesis led to a combined
defect of mitochondrial respiratory chain
complexes which were responsible for
the human disease (Yarham et al.,21, March 3, 2015 ª2015 Elsevier Inc. 351
Figure 1. Human Diseases Caused by Abnormal Modification of mt-tRNAs
The figure illustrates the variety of clinical presentations caused by abnormal mt-tRNAmodification due to
mutations in nuclear genes.
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ciencies of i6A37 tRNA modification
should be considered a potential mecha-
nism of human disease caused by both
nuclear gene and mtDNA mutations.
Altered tRNA modification was also
documented to contribute to the patho-
mechanism of two common pathogenic
mt-tRNA mutations (m.3243A > G, which
causes mitochondrial encephalomyop-
athy with lactic acidosis and stroke-like
episodes [MELAS], and m.8344A > G,
which causes myoclonic epilepsy with
ragged-red fibers [MERRF]) (Suzuki and
Suzuki, 2014), and in m.3243A>G cy-
brids, the expression of mt-tRNA-modi-
fying enzymes was modulated by micro-
RNA-9/9*.
A novel role of the cell-cycle regu-
lation enzyme cyclin-dependent protein
kinase 5 (CDK5) was recently shown
to regulate the synthesis of both mito-
chondrial and cytoplasmic proteins
(Reiter et al., 2012). An aberrant regulation
of CDK5 leads to the development
of various neurodegenerative diseases
including Alzheimer’s disease. Recently,
CDK5RAP1 was shown to inhibit the
active CDK5 kinase through a complex
modification step (N6-isopentenyladeno-352 Cell Metabolism 21, March 3, 2015 ª201sine [i(6)A] into 2-methylthio-N6-isopente-
nyladenosine [ms(2)i(6)A]). This conver-
sion affected both mitochondrial and
cytosolic tRNAs, providing a link between
kinase-based protein modification and
RNA modification (Reiter et al., 2012). In
this issue, Wei et al. (2015) advance our
understanding of this important pathway
by showing that another regulatory
unit—Cdk5 regulatory subunit-associ-
ated protein-like-1 (CDKAL1)—is respon-
sible for 2-methylthio (ms2) modification
of cytosolic tRNALys(UUU), and the mito-
chondrial tRNAs, mt-tRNASer(UCN), mt-
tRNAPhe, mt-tRNATyr, and mt-tRNATrp.
Homozygous Cdkal1 knockout mice
developed a respiratory chain deficiency
due to abnormal intramitochondrial pro-
tein synthesis, and under stress condi-
tions (ketogenic diet) these mice devel-
oped myopathy and cardiomyopathy.
More importantly, Wei et al. (2015)
showed that ms2 modifications of mt-
tRNAs are sensitive to oxidative stress,
and are reduced in peripheral blood
cells of MELAS patients carrying the
m.3243A > G mutation. Patients with the
m.3243A > G mtDNA mutation invariably
harbor a mixture of mutated and wild-
type mtDNA (heteroplasmy) in varying5 Elsevier Inc.proportions. Wei et al. (2015) harnessed
this complexity to show a correlation
between the percentage level of the
m.3243A > G mutation and the degree of
ms2 modification. Given that the level of
heteroplasmy correlates with the clinical
features, their findings provide strong
evidence that the mt-tRNA modifications
contribute to the pathogenesis of this
common mitochondrial disorder.
Taken together, these findings raise
the possibility that similar tRNA modifi-
cations play a crucial role in regulating
cellular energy delivery in response to
local needs, and also implicate dysfunc-
tional mt-tRNA modifications in other
mtDNA tRNA disorders. This is exciting,
because at present the large group of
inherited disorders of intramitochondrial
protein synthesis have no treatment.
Unveiling this new mechanism presents
a tractable target that can be manipulated
by external factors, perhaps leading us
to the treatment ‘‘holy grail.’’
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